Project Grant 2507762
Award Date
5/15/25
Completion Date
1/31/26
Dollars Obligated
$303K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Foragr Medicines, Inc. will support the development of a high-throughput platform for small molecule, in-cell targeting of undruggable proteins via their mRNAs. The project aims to create an efficient and cost-effective approach for developing therapeutics for previously undruggable diseases, including hard-to-treat neurodegenerative diseases and aggressive cancers....
The National Science Foundation (NSF) awarded a $303,864 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics Inc., a for-profit organization located in Ladera Ranch, CA. The grant, awarded on April 1, 2025, aims to develop a platform for discovering and rapidly developing disruptive drug candidates by determining the mechanisms driving diseases at the molecular network level. The project objectives include demonstrating that...
This $750,000 Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences (CFDA 47.049) program supports the development of a novel platform to enable rapid and robust identification of functional RNA molecules directly within mammalian cellular environments. The research aims to solve the challenge of RNA structure sensitivity to local environments that has hindered progress in the field of functional RNA discovery. The project will deliver a customized...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Junipero Therapeutics, Inc. aims to develop an innovative gene therapy platform using epigenome editing techniques. The project seeks to overcome limitations of current gene therapy methods by leveraging oligonucleotide-conjugates to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible manner. The research plan...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project awarded to Multitarga LLC aims to develop an adaptive multi-targeted priming platform, called HostPathEP, to improve the sensitivity and specificity of RNA sequencing for detecting low-abundance pathogen transcripts in complex host-pathogen samples. The $304,995 award, effective June 1, 2025 through May 31, 2026, will fund the development of...
The National Science Foundation (NSF) awarded a $275,000 SBIR Phase I grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Om Therapeutics Inc. in La Jolla, CA. The goal of this project is to enable the discovery of new medicines at an unprecedented rate by empowering researchers to launch drug discovery programs quickly and cost-effectively. The innovation involves the ability to screen billions of unique small molecules against the entire human proteome in a...
This National Science Foundation (NSF) Project Grant, awarded under the Biological Sciences program (CFDA 47.074), provides $750,000 to Stanford University to develop new technologies for studying RNA, the essential molecules that carry genetic information and play crucial roles in cell functions. The key products and services to be delivered under this 3-year award include: Creating non-destructive methods to directly study RNA localization and interactions within living cells, achieving...
This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) was provided to Femtofluidics Incorporated, a for-profit organization, to develop a device that can rapidly and inexpensively synthesize DNA-encoded libraries (DELs) for drug discovery applications. The $274,932 award, effective from January 1, 2025 to August 31, 2025, supports the company's efforts to build an electronic substrate-based system that can...